Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Only 12 employees

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Jun 29, 2021 9:06am

149 Views

Post# 33465208

RE:Only 12 employees

That's a cop out... They need to hire more people if they can't keep schedule if it is due to delays on their end (collecting data, analyzing data, creating apporval submissions for FDA) vs FDA review delays ... they have had additional funding for a few months now... build the team to execute and start acting like a biotech that has a PH3 multl billion dollar drug...

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario